Approval · Notice of Compliance 27712 · 2022
YERVOY: Notice of Compliance 27712
Issued March 3, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27712
- Date
- March 3, 2022
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Reduction of Indication: Unresectable or Metastatic Melanoma New Indications:Metastatic Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H)/ Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer. Unresectable Malignant Pleural Mesothelioma (MPM):
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| YERVOY | Not yet assigned | — |
Medicinal ingredients
- IPILIMUMAB 5 MG per ML